drugset / Trial / NCT03406260

A Study of Lasmiditan in Healthy Elderly Participants

NCT03406260

Phase 1 Completed 36 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The purposes of this study are to evaluate the effect of lasmiditan on blood pressure, as well as to look at the amount of study drug that gets into the blood stream and how long it takes the body to get rid of it in healthy elderly participants. The tolerability of the study drug will also be evaluated. Information about any side effects that may occur will also be collected. This study will take about 11 days, not including screening. Screening is required within 28 days prior to the start of the study.

Timeline

Start
2018-01-25
Primary completion
2018-04-13
Completion
2018-04-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Lasmiditan Small molecule 100 mg Oral
Subject Lasmiditan Small molecule 200 mg Oral

Indications

No indication recorded.